Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development

Nav

General Info

Geography

United States of America (USA)

Coverage type

Country

Time period covered

01/2009 - 12/2012

Data type

Scientific literature

Keywords

HIV and AIDS, Health care costs, Health care expenditures

Citation

Authors

Morris BL, Scott CA, Wilkin TJ, Sax PE, Gulick RM, Freedberg KA, Schackman BR

Journal

HIV Clin Trials

Volume

Issue

Pages

1-10

Publication year

2012

Suggested citation

Morris BL, Scott CA, Wilkin TJ, Sax PE, Gulick RM, Freedberg KA, Schackman BR. Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development. HIV Clin Trials. 2012; 13(1): 1-10.

DOI

10.1310/hct1301-001

PMID

22306583

GHDx Entry last modified on: Apr 10, 2023

Header sites

Search form

Main menu

Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development

Nav